Bonnie Gillis

The explosion of new drugs for the treatment of castration-resistant prostate cancer (CRPC) is a welcome advance, but raises questions about how best to sequence these drugs with standard docetaxel chemotherapy.

Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.

A phase III study shows noninferiority of accelerated partial breast irradiation as compared to conventional whole breast irradiation.

Hypofractionation, known as delivering higher doses of radiation in fewer fractions, appears to be feasible and non-inferior compared with conventional fractionated radiotherapy.

Coordinating radiation therapy teams and palliative care teams based on patient reported outcomes from University of Virginia Health System improved outpatient symptom management and decreased end-of-life hospitalizations, as well as costs of care for patients with late-stage cancer.

Tasquinimod demonstrated promise in phase II trials but failed to improve overall survival in a phase III trial in treatment-naive metastatic castration-resistant prostate cancer; some experts believe this failure highlights the need for more intelligent clinical trial designs in prostate cancer.

Accelerated hypofractionated radiotherapy using a schedule of 60 Gy in 20 fractions of 3 Gy delivered in 4 weeks was found to be comparable to the conventional schedule of 74 Gy/37 of 2 GY delivered in 7.2 weeks in patients with localized prostate cancer taking androgen deprivation therapy.

A subanalysis of the ALSYMPCA trial suggests that chemotherapy can be safely administered after treatment with radium-223 in patients with metastatic CRPC and bone metastasis.

Evidence is mounting for multigene panel testing in women with suspected familial breast and/or ovarian cancer.

Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA- 1 trial.

An analysis of the phase III AFFIRM trial showed that enzalutamide significantly delayed the time to first skeletal-related event and significantly improved pain and quality of life compared with placebo in men with mCRPC who had received prior docetaxel.